Angelini Ventures

Headquarter
Copenhagen, Denmark

Milestones
Founded: 2020
Invested: 2023

Founders / CEO
Colleen Acosta, CEO

Vertical
Biotech

Board Participation
Paolo di Giorgio, Board Member

Website

Linkedin

Freya™ is a clinical-stage company taking an innovative approach to women’s health, with microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of reproductive system diseases uniquely afflicting women.
Freya’s drug candidates comprise full-spectrum microbiota and rationally-selected strain consortia, which have the potential to restore an optimal, non-inflammatory vaginal microbiome.

Related news:

Freya Biosciences announces $38 Million funding in one of the largest Series A raises to advance women’s reproductive immunotherapies. Funding comes on the heels of positive top-line clinical results and will advance clinical development of its lead drug candidate